At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the anti-CD38 monoclonal antibody, daratumumab, for the treatment of patients with pretreated multiple myeloma.
Daratumumab for heavily pretreated multiple myeloma
26th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?